ESMO 2024 Highlights: Presenter Vignette – Rosie Voorthuis

Dr. Rosie Voorthuis

Rosie Voorthuis

PhD, student

Netherlands Cancer Institute

Abstract# LBA20

First-line carboplatin-cyclophosphamide (CC) versus paclitaxel (P) with or without atezolizumab (atezo) for metastatic triple negative breast cancer (mTNBC): Results from a multicenter, randomized phase IIb trial: The Triple-B study (BOOG 2013-01)